(Q64046612)
Statements
Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS (English)
0 references
31 July 2008
0 references
9 March 2012
0 references
220
0 references
18 year
0 references
55 year
0 references